Trial Condition(s):

Biochemically recurrent prostate cancer

A study to compare darolutamide given with Androgen Deprivation Therapy (ADT) with ADT in men with nonmetastatic prostate cancer and raise of Prostate Specific Antigen (PSA) levels after local therapies (ARASTEP)

Bayer Identifier:

21492

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available

Not Yet Recruiting

Trial Purpose

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.

BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy, the blood level of a specific protein called PSA rises. PSA is a marker for prostate cancer development. This may mean that the cancer has come back even though no cancer or cancer spreading is yet detectable using conventional imaging such as computed tomography (CT) scans, magnetic resonance imaging (MRI) and bone scans. Recently a more sensitive imaging method called prostate-specific membrane antigen [PSMA] positron emission tomography [PET]) /computed tomography [CT]) scan may identify prostate cancer lesions not detectable by conventional imaging. Men with BCR have a higher risk of their cancer spreading to other parts of the body, particularly men with a stage of prostate cancer where the PSA levels raised to a certain limit within a specified period of time after local therapies. Once the cancer spreads to other parts of the body, it can become even harder to treat.

In men with prostate cancer, male sex hormones (also called androgens) like testosterone can help the cancer grow and spread. To reduce androgens levels in these patients, there are treatments that block androgens production in the body called androgen deprivation therapy (ADT). ADT is often used to stop prostate cancer. Another way to stop prostate cancer growth and spread is to block the action of androgen receptors on prostate cancer cells. Next generation androgen receptor inhibitors (ARIs) including darolutamide can block the action of androgens receptors and are available for the treatment of prostate cancer in addition to ADT. It is already known that men with prostate cancer benefit from these treatments.

The main objective of this study is to learn if the combination of darolutamide and ADT prolongs the time that the participants live without their cancer getting worse, or to death due to any cause, compared to placebo and ADT given for 24 months. A placebo is a treatment that looks like a medicine but does not have any medicine in it.

To do this, the study team will measure the time from the date of treatment allocation to the finding of new cancer spread in the participants by using PSMA PET/CT, or death due to any cause. The PSMA PET/CT scans is performed using a radioactive substance called a “tracer” that specifically binds to the prostate-specific membrane antigen (PSMA) which is a protein often found in large amounts on prostate cancer cells.

To avoid bias in treatment, the study participants will be randomly (by chance) allocated to one of two treatment groups. Based on the allocated treatment group, the participants will either take darolutamide plus ADT or placebo plus ADT twice daily as tablets by mouth. The study will consist of a test (screening) phase, a treatment phase and a follow-up phase. The treatment duration will be 24 months unless the cancer gets worse, the participants have medical problems, or they leave the study for any reason. In addition, image guided radiotherapy (IGRT) or surgery is allowed and your doctor will explain the benefits and risks of this type of therapy.

During the study, the study team will:
•    take blood and urine samples.
•    measure PSA and testosterone levels in the blood samples
•    do physical examinations
•    check the participants’ overall health
•    examine heart health using electrocardiogram (ECG)
•    check vital signs
•    check cancer status using PSMA PET/CT scans, CT, MRI and bone scans
•    take tumor samples (if required)
•    ask the participants if they have medical problems

About 30 days after the participants have taken their last treatment, the study doctors and their team will check the participants’ health and if their cancer worsened. The study team will continue to check this and regularly ask the participants questions about medical problems and subsequent therapies until they leave the study for any reason or until they leave the study for any reason or until the end of the study, whatever comes first.

Inclusion Criteria
- Capable of giving signed informed consent as described which includes compliance with the requirements, restrictions listed in the informed consent form (ICF), and in this protocol.
- Male ≥18 years of age at the time of signing the informed consent.
- Histologically or cytologically confirmed adenocarcinoma of prostate.
- Prostate cancer initially treated by: radical prostatectomy (RP) followed by adjuvant radiotherapy (ART), or salvage radiotherapy (SRT), or RP in participants who are unfit for ART or SRT, or primary radiotherapy (RT).
- High-risk biochemical recurrence (BCR), defined as Prostate-specific antigen doubling time (PSADT) <12 months calculated using the formula provided by the Sponsor, and PSA ≥0.2 ng/mL after ART or SRT post RP or after RP in participants who are unfit for ART or SRT, or PSA ≥2 ng/mL above the nadir after primary RT only.
- Participants must undergo prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) within the 30-day Screening period using either 18F-DCFPyL (piflufolastat F 18) or 68Ga-PSMA-11 which will be assessed by BICR.
- Serum testosterone ≥150 ng/dL (5.2 nmol/L).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Blood counts at screening: Hemoglobin ≥9.0 g/dL (participant must not have received blood transfusion within 7 days prior to sample being taken); Absolute neutrophil count (ANC) ≥1.5x10^9/L (participant must not have received any growth factor within 4 weeks prior to sample being taken); Platelet count ≥100x10^9/L.
- Screening values of: Alanine aminotransferase (ALT) ≤1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) ≤1.5 x ULN; Total bilirubin (TBL) ≤1.5 ULN, (except participants with a diagnosis of Gilbert’s disease); Estimated glomerular filtration rate (eGFR) >40 ml/min/1.73 m^2 calculated by the CKD-EPI formula.
- Sexually active male participants must agree to use contraception as detailed in the protocol during the Treatment period and for at least 3 months after the last dose of study treatment, and refrain from donating sperm during this period.
Exclusion Criteria
- Pathological finding consistent with small cell, ductal or ≥50 % component of neuroendocrine carcinoma of the prostate.
- History of bilateral orchiectomy.
- Metastases or recurrent /new malignant lesions in prostate gland/bed seminal vesicles, lymph nodes below the CIA bifurcation on conventional imaging (CI) as assessed by BICR during screening.
- Brain metastasis on PSMA PET /CT by BICR at screening. 
- High-risk BCR after primary radiotherapy with new loco-regional lesions on screening PSMA PET/CT who are eligible for curative salvage prostatectomy. 
Note: Participants treated with curative salvage prostatectomy after primary RT who meet the PSA criteria (inclusion criteria 5) may be considered for the study. 
- Prior treatment with second generation (e.g. enzalutamide, apalutamide) androgen receptor inhibitors (ARIs) and CYP 17 inhibitors (e.g., abiraterone) within 18 months prior to signing of the ICF. 
- Prior treatments with PSMA-radiotherapeutics within 12 months prior to randomization.
- Prior radiotherapy (including image-guided radiotherapy) as primary, adjuvant or salvage treatment completed within 8 weeks prior to signing of the ICF.
- Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years.
- History of pelvic radiotherapy for other malignancy.

Trial Summary

Enrollment Goal
750
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
Yes
Products
Darolutamide+ADT (BAY1841788)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Universitätsklinikum AKH Wien

Wien, Austria, 1090

Status
Not yet recruiting
Locations

Ordensklinikum Linz GmbH Elisabethinen

Linz, Austria, 4020

Status
Not yet recruiting
Locations

Krankenhaus der Barmherzigen Brüder

Wien, Austria, 1020

Status
Not yet recruiting
Locations

Dana-Farber Cancer Institute

Boston, United States, 02115-6084

Status
Not yet recruiting
Locations

Carolina Urological Research Center

Myrtle Beach, United States, 29579

Status
Not yet recruiting
Locations

Colorado Urology (Colorado Clinical Research)

Lakewood, United States, 80228

Status
Not yet recruiting
Locations

Urology San Antonio Research, PA

San Antonio, United States, 78229

Status
Not yet recruiting
Locations

White Plains Hospital

White Plains, United States, 10601

Status
Not yet recruiting
Locations

First Urology PSC

Jeffersonville, United States, 47130

Status
Not yet recruiting
Locations

Tower Urology, Inc

Los Angeles, United States, 90048

Status
Not yet recruiting
Locations

MidLantic Urology

Bala Cynwyd, United States, 19004

Status
Not yet recruiting
Locations

Alliance Urology

Greensboro, United States, 27403

Status
Not yet recruiting
Locations

Ohio State University Wexner Medical Center

Columbus, United States, 43210

Status
Not yet recruiting
Locations

Arizona Institute of Urology

Tucson, United States, 85704

Status
Not yet recruiting
Locations

New Jersey Urology, LLC

Voorhees, United States, 08043

Status
Not yet recruiting
Locations

Associated Medical Professionals of NY, PLLC

Syracuse, United States, 13210

Status
Not yet recruiting
Locations

Urological Associates of Lancaster

Lancaster, United States, 17604

Status
Not yet recruiting
Locations

Bon Secours St. Francis Hospital

Greenville, United States, 29607

Status
Not yet recruiting
Locations

University of Florida - Jacksonville

Jacksonville, United States, 32209

Status
Not yet recruiting
Locations

Barbara Ann Karmanos Cancer Institute - Detroit

Detroit, United States, 48201

Status
Not yet recruiting
Locations

University of Kansas

Kansas City, United States, 66160

Status
Not yet recruiting
Locations

University of Southern California

Los Angeles, United States, 90033

Status
Not yet recruiting
Locations

University of California, Los Angeles

Los Angeles, United States, 90095

Status
Not yet recruiting
Locations

Comprehensive Cancer Center

Chicago, United States, 60637

Status
Not yet recruiting
Locations

NYU Langone Health

New York, United States, 10016

Status
Not yet recruiting
Locations

University of Texas MD Anderson Cancer Center

Houston, United States, 77030

Status
Not yet recruiting
Locations

Urology of Indiana, LLC

Greenwood, United States, 46143

Status
Not yet recruiting
Locations

Johns Hopkins Univ School Med|Sidney Kimmel Comp Cancer Cntr

Baltimore, United States, 21231

Status
Not yet recruiting
Locations

Urology Austin, PLLC (an affiliate of Urology America)

Austin, United States, 78759

Status
Not yet recruiting
Locations

Clermont Oncology Center

Clermont, United States, 34711

Status
Not yet recruiting
Locations

Mayo Clinic Hospital

Phoenix, United States, 85054

Status
Not yet recruiting
Locations

Wake Forest Baptist Health

Winston Salem, United States, 27157

Status
Not yet recruiting
Locations

Mid Florida Cancer Centers

Orange City, United States, 32763-8316

Status
Not yet recruiting
Locations

Jesse Brown VA Medical Center

Chicago, United States, 60612

Status
Not yet recruiting
Locations

University of Pittsburgh

Pittsburgh, United States, 15232

Status
Not yet recruiting
Locations

The Urology Group

Cincinnati, United States, 45212

Status
Not yet recruiting
Locations

UCSF Med Center Helen Diller Family Comp Cancer Center

San Francisco, United States, 94143

Status
Not yet recruiting
Locations

City of Hope National Medical Center

Durate, United States, 91010

Status
Not yet recruiting
Locations

Washington University School of Medicine

St. Louis, United States, 63110-1093

Status
Not yet recruiting
Locations

Institut de Cancerologie de Ouest - Saint Herblain

St Herblain, France, 44805

Status
Not yet recruiting
Locations

Gustave Roussy (Institut de Cancerologie Gustave-Roussy)

Villejuif, France, 94805

Status
Not yet recruiting
Locations

Hôpital Pellegrin - Bordeaux

BORDEAUX, France, 33000

Status
Not yet recruiting
Locations

Hopital Bichat - Paris

PARIS, France, 75018

Status
Not yet recruiting
Locations

Centre Hospitalier Lyon Sud

PIERRE BENITE, France, 69495

Status
Not yet recruiting
Locations

Centre Jean Perrin

CLERMONT-FERRAND, France, 63011

Status
Not yet recruiting
Locations

Hôpital Claude Huriez - Lille

LILLE, France, 59037

Status
Not yet recruiting
Locations

Hôpital Pontchaillou

RENNES CEDEX, France, 35033

Status
Not yet recruiting
Locations

Uniklinikum Salzburg - Landeskrankenhaus

Salzburg, Austria, 5020

Status
Not yet recruiting
Locations

Mount Vernon Cancer Centre

Northwood, United Kingdom, HA6 2RN

Status
Not yet recruiting
Locations

Royal Marsden Hospital (London)

London, United Kingdom, SW3 6JJ

Status
Not yet recruiting
Locations

Charing Cross Hospital

London, United Kingdom, W6 8RF

Status
Not yet recruiting
Locations

University of Minnesota Medical Center

Minneapolis, United States, 55455

Status
Not yet recruiting
Locations

University of California Irvine Medical Center

Orange, United States, 92868-3201

Status
Not yet recruiting
Locations

Northwestern University Feinberg School of Medicine

Chicago, United States, 60611

Status
Not yet recruiting
Locations

Michigan Institute of Urology, PC

Troy, United States, 48084

Status
Not yet recruiting
Locations

Hospital Clínico Universitario de Santiago de Compostela

Santiago de Compostela, Spain, 15706

Status
Not yet recruiting
Locations

Hospital Universitario Puerta del Mar

Cadiz, Spain, 11009

Status
Not yet recruiting
Locations

MD Anderson International Espanya, S.A.

Madrid, Spain, 28033

Status
Not yet recruiting
Locations

Hospital Virgen de la Victoria

Málaga, Spain, 29010

Status
Not yet recruiting
Locations

Hospital del Mar

Barcelona, Spain, 08003

Status
Not yet recruiting
Locations

Hospital Clínic i Provincial de Barcelona

Barcelona, Spain, 08023

Status
Not yet recruiting
Locations

Ciutat Sanitaria i Universitaria de la Vall d'Hebron

Barcelona, Spain, 08035

Status
Not yet recruiting
Locations

Hospital Fundació Puigvert

Barcelona, Spain, 08025

Status
Not yet recruiting
Locations

Instituto Valenciano de Oncología

Valencia, Spain, 46009

Status
Not yet recruiting
Locations

Hospital Universitari i Politècnic La Fe

Valencia, Spain, 46026

Status
Not yet recruiting
Locations

Hospital Ramón y Cajal

Madrid, Spain, 28034

Status
Not yet recruiting
Locations

H. General Uiversitario Morales Meseguer - Department of Urology

Murcia, Spain, 30008

Status
Not yet recruiting
Locations

Hospital Madrid Norte Sanchinarro

Madrid, Spain, 28050

Status
Not yet recruiting
Locations

Princess Margaret Cancer Centre - UHN

Toronto, Canada, M5G 2M9

Status
Not yet recruiting
Locations

Hamilton Health Sciences-Juravinski Cancer Centre

Hamilton, Canada, L8V 5C2

Status
Not yet recruiting
Locations

Sir Mortimer B. Davis Jewish General Hospital

Montreal, Canada, H3T 1E2

Status
Not yet recruiting
Locations

Vancouver General Hospital

Vancouver, Canada, V6H 3Z6

Status
Not yet recruiting
Locations

Prostate Cancer Centre

Calgary, Canada, T2V 1P9

Status
Not yet recruiting
Locations

Hopital Hotel-Dieu de Levis

Levis, Canada, G6V 3Z1

Status
Not yet recruiting
Locations

BCCA-Vancouver Island Centre

Victoria, Canada, V8R 6V5

Status
Not yet recruiting
Locations

Rambam Health Corporation

Haifa, Israel, 3109601

Status
Not yet recruiting
Locations

Hadassah Hebrew University Hospital Ein Kerem

Jerusalem, Israel, 9112001

Status
Not yet recruiting
Locations

Clalit Health Services Rabin Medical Center-Beilinson Campus

Petah Tikva, Israel, 4941492

Status
Not yet recruiting
Locations

Macquarie University Hospital

Macquarie University, Australia, 2109

Status
Not yet recruiting
Locations

GenesisCare Newcastle

Newcastle, Australia, 2290

Status
Not yet recruiting
Locations

Prince of Wales Hospital NSW

Randwick, Australia, 2031

Status
Not yet recruiting
Locations

St Vincents Hospital Sydney

Sydney, Australia, 2010

Status
Not yet recruiting
Locations

Austin Health

Heidelberg, Australia

Status
Not yet recruiting
Locations

Liverpool Hospital

Liverpool, Australia, 2170

Status
Not yet recruiting
Locations

Sydney Adventist Hospital

Wahroonga, Australia, 2076

Status
Not yet recruiting
Locations

Port Macquarie Base Hospital

Port Macquarie, Australia, 2444

Status
Not yet recruiting
Locations

Epworth HealthCare

East Melbourne, Australia, 3002

Status
Not yet recruiting
Locations

Tasman Health Care

Southport, Australia, 4215

Status
Not yet recruiting
Locations

IPO Lisboa

Lisboa, Portugal, 1099-023

Status
Not yet recruiting
Locations

Hospital da Luz - Lisboa

Lisboa, Portugal, 1500-650

Status
Not yet recruiting
Locations

University College London Hospitals NHS Foundation Trust

London, United Kingdom, NW1 2PQ

Status
Not yet recruiting
Locations

Bedford Hospital - Bedfordshire Hospitals NHS Foundation Tru

Bedford, United Kingdom, MK42 9DJ

Status
Not yet recruiting
Locations

Canterbury Urology Research Trust

Christchurch, New Zealand, 8013

Status
Not yet recruiting
Locations

Auckland City Hosptial

Auckland, New Zealand

Status
Not yet recruiting
Locations

Tauranga Urology Research Limited

Tauranga, New Zealand, 3112

Status
Not yet recruiting
Locations

Assistência Multidisciplinar em Oncologia (AMO)

Salvador, Brazil, 41950-640

Status
Not yet recruiting
Locations

Instituto do Câncer do Estado de São Paulo

São Paulo, Brazil, 01246-000

Status
Not yet recruiting
Locations

Faculdade de Medicina do ABC

Santo André, Brazil, 09060-650

Status
Not yet recruiting
Locations

Inst. de Assistência Médica ao Sérvidor Público Estadual

São Paulo, Brazil, 04039-004

Status
Not yet recruiting
Locations

Liga Norte Riograndense Contra o Câncer

Natal, Brazil, 59062-000

Status
Not yet recruiting
Locations

Hospital Sirio Libanes

Sao Paulo, Brazil, 01308-050

Status
Not yet recruiting
Locations

Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner

Curitiba, Brazil, 81520-060

Status
Not yet recruiting
Locations

Universitätsklinikum Münster (UKM)

Münster, Germany, 48149

Status
Not yet recruiting
Locations

Klinikum rechts der Isar

München, Germany, 81675

Status
Not yet recruiting
Locations

Universitätsmedizin der Georg-August-Universität Göttingen

Göttingen, Germany, 37075

Status
Not yet recruiting
Locations

Universitätsklinikum Köln

Köln, Germany, 50937

Status
Not yet recruiting
Locations

Klinikum der Universität Würzburg

Würzburg, Germany, 97080

Status
Not yet recruiting
Locations

Städtisches Klinikum Braunschweig gGmbH

Braunschweig, Germany, 38126

Status
Not yet recruiting
Locations

Medizinische Fakultät der Otto-von-Guericke Universität

Magdeburg, Germany, 39120

Status
Not yet recruiting
Locations

Klinikum der Johann-Wolfgang-Goethe-Universitaet Frankfurt M

Frankfurt a. M., Germany, 60590

Status
Not yet recruiting
Locations

Studienpraxis Urologie

Nürtingen, Germany, 72622

Status
Not yet recruiting
Locations

ICANS - Institut de Cancérologie de Strasbourg Europe

STRASBOURG, France, 67033

Status
Not yet recruiting
Locations

Hôpital Bretonneau

TOURS, France, 37044

Status
Not yet recruiting
Locations

Tokyo Medical and Dental University Hospital

Bunkyo-ku, Japan, 113-8519

Status
Not yet recruiting
Locations

Kyoto University Hospital

Kyoto, Japan, 606-8507

Status
Not yet recruiting
Locations

Hokkaido University Hospital

Sapporo, Japan, 060-8648

Status
Not yet recruiting
Locations

Kanazawa University Hospital

Kanazawa, Japan, 920-8641

Status
Not yet recruiting
Locations

Osaka University Hospital

Suita, Japan, 565-0871

Status
Not yet recruiting
Locations

Yokohama City University Hospital

Yokohama, Japan, 236-0004

Status
Not yet recruiting
Locations

Kagoshima University Hospital

Kagoshima, Japan, 890-8520

Status
Not yet recruiting
Locations

Ospedale San Raffaele s.r.l.

Milano, Italy, 20132

Status
Not yet recruiting
Locations

A.O.U.I. Verona

Verona, Italy, 37126

Status
Not yet recruiting
Locations

A.O.U. Consorziale Policlinico

Bari, Italy, 70124

Status
Not yet recruiting
Locations

A.O.U. di Modena - Policlinico

Modena, Italy, 41124

Status
Not yet recruiting
Locations

IRCCS Centro di Riferimento Oncologico (CRO)

Pordenone, Italy, 33081

Status
Not yet recruiting
Locations

A.O. di Perugia - Ospedale Santa Maria della Misericordia - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA

Perugia, Italy, 06123

Status
Not yet recruiting
Locations

IRCCS Ist Nazionale Tumori GE - Oncologia Medica

Genova, Italy, 16132

Status
Not yet recruiting
Locations

Santa Chiara Hospital

Trento, Italy, 38122

Status
Not yet recruiting
Locations

Istituto Nazionale Tumori IRCCS Fondazione G.Pascale

Napoli, Italy, 80131

Status
Not yet recruiting
Locations

AUSL-IRCCS di Reggio Emilia

Reggio Emilia, Italy, 42123

Status
Not yet recruiting
Locations

Fondazione IRCCS Istituto Nazionale dei Tumori

Milano, Italy, 20133

Status
Not yet recruiting
Locations

Molinette Hospital University of Torino

Torino, Italy, 10126

Status
Not yet recruiting
Locations

IRCCS Istituti Fisioterapici Ospitalieri - IFO

Roma, Italy, 00144

Status
Not yet recruiting
Locations

AUSL di Bologna

Bologna, Italy, 40139

Status
Not yet recruiting
Locations

Virgen del Rocio University Hospital - Oncology Department

Sevilla, Spain, 41013

Status
Not yet recruiting
Locations

Fundacao Champalimaud

Lisboa, Portugal, 1400-038

Status
Not yet recruiting
Locations

Centro Hospitalar Universitário de Lisboa Norte | Heart and Vessels Department

Lisboa, Portugal, 1649-028

Status
Not yet recruiting
Locations

Hospital CUF Tejo

Lisboa, Portugal, 1350-352

Status
Not yet recruiting
Locations

Centro Clinico Academico - Braga

Braga, Portugal, 4710-243

Status
Not yet recruiting
Locations

Hospital Israelita Albert Einstein

São Paulo, Brazil, 05651-901

Status
Not yet recruiting
Locations

Hospital Moinhos de Vento-Centro Clínico

Porto Alegre, Brazil, 90035-001

Status
Not yet recruiting
Locations

Docrates Klinikka

Helsinki, Finland, 00180

Status
Not yet recruiting
Locations

Turun yliopistollinen keskussairaala

Turku, Finland, FIN-20521

Status
Not yet recruiting
Locations

Oulun yliopistollinen sairaala

Oulu, Finland, 90220

Status
Not yet recruiting
Locations

Tampereen yliopistollinen sairaala, keskussairaala

Tampere, Finland, 33520

Status
Not yet recruiting
Locations

HUS, Meilahden sairaala

Helsinki, Finland, 00290

Status
Not yet recruiting
Locations

Royal Surrey County Hospital NHS Foundation Trust

Guildford, United Kingdom, GU2 7WG

Status
Not yet recruiting
Locations

Institut Curie - Ulm - Paris

PARIS cedex 5, France, 75248

Status
Not yet recruiting
Locations

CHU GRENOBLE - Hopital Michallon

GRENOBLE, France, 38048

Status
Not yet recruiting
Locations

A.O.U. Ospedali Riuniti Foggia

Foggia, Italy, 71100

Status
Not yet recruiting
Locations

Royal Prince Alfred Hospital

Camperdown, Australia, 2050

Status
Not yet recruiting
Locations

Eastern Clinical Research Unit - Box Hill

Box Hill, Australia, 3128

Status
Not yet recruiting
Locations

Bundaberg Hospital, Genesis Cancer Care - Bundaberg

Bundaberg, Australia, 4670

Status
Not yet recruiting
Locations

Wide Bay Hospital and Health Service - Hervey Bay Hospital

Pialba, Australia, 4655

Status
Not yet recruiting
Locations

Medizinische Universität Innsbruck

Innsbruck, Austria, 6020

Status
Not yet recruiting
Locations

Shaare Zedek Medical Center

Jerusalem, Israel, 9372212

Status
Not yet recruiting
Locations

Sheba Medical Center

Tel Hashomer, Israel, 52621

Status
Not yet recruiting
Locations

Sourasky Medical Center

Tel-Aviv, Israel, 64239

Status
Not yet recruiting
Locations

The Urology Place

San Antonio, United States, 78257

Status
Not yet recruiting
Locations

IOV Castelfranco Veneto

Castelfranco Veneto, Italy, 31033

Status
Not yet recruiting
Locations

IRCCS Ospedale Sacro Cuore Don Calabria

Verona, Italy, 37024

Status
Not yet recruiting
Locations

ASST Papa Giovanni XXIII

Bergamo, Italy, 24127

Status
Not yet recruiting
Locations

Policlinico Tor Vergata

Roma, Italy, 00133

Status
Not yet recruiting
Locations

Klinikum Mannheim GmbH Universitaetsklinikum

Mannheim, Germany, 68167

Status
Not yet recruiting
Locations

Allegheny General Hospital

Pittsburgh, United States, 15212

Status
Not yet recruiting
Locations

IRCCS Ist Clinico Humanitas

Rozzano, Italy, 20089

Status
Not yet recruiting
Locations

Vivantes Klinikum Am Urban

Berlin, Germany, 10967

Status
Not yet recruiting
Locations

Skane University Hospital - Department of Urology

Malmo, Sweden, 20502

Status
Not yet recruiting
Locations

Goteborgs Universitet

Gothenburg, Sweden, 413 45

Status
Not yet recruiting
Locations

Rigshospitalet

Copenhagen, Denmark, 2100

Status
Not yet recruiting
Locations

Charité Campus Benjamin Franklin (CBF)

Berlin, Germany, 12203

Status
Not yet recruiting
Locations

Universitätsklinikum Carl Gustav Carus Dresden

Dresden, Germany, 01307

Status
Not yet recruiting
Locations

Policlinico Gemelli

Rome, Italy, 168

Status
Not yet recruiting
Locations

A.O.U. di Bologna Policlinico S.Orsola Malpighi

Bologna, Italy, 40138

Status
Not yet recruiting
Locations

Aarhus Universitetshospital

Aarhus N, Denmark, 8200

Status
Not yet recruiting
Locations

Aalborg University Hospital

Aalborg, Denmark, 9000

Status
Not yet recruiting
Locations

London Regional Cancer Program

London, Canada, N6A 4L6

Status
Not yet recruiting
Locations

Cabrini Medical Centre

Malvern, Australia, 3144

Status
Not yet recruiting
Locations

Nanjing First Hospital

Nanjing, China, 210006

Status
Not yet recruiting
Locations

Peking Union Medical College Hospital (PUMCH) - East Location

Beijing, China, 100730

Status
Not yet recruiting
Locations

The 1st Affiliated Hospital of Zhejiang University

Hangzhou, China, 310000

Status
Not yet recruiting
Locations

New Jersey Urology (NJU)

Saddle Brook, United States, 07663-5227

Status
Not yet recruiting
Locations

Nova Scotia Health Authority

Halifax, Canada, B3H 2Y9

Status
Not yet recruiting
Locations

Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hopital Fleurimont

Sherbrooke, Canada, J1H 5N4

Status
Not yet recruiting

Trial Design